Current role
General Counsel
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About General Counsel
The proxy statement of Health Catalyst, Inc. reports total compensation of $1,519,532 for General Counsel in fiscal 2022, including a base salary of $300,000. Disclosed compensation is on record for 3 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Health Catalyst, Inc. (HCAT)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Health Catalyst, Inc.
Other people whose current roles at this company are on record from its filings.
- Ben Albert CEO
- Simeon Kohl CEO, Board Member
- John A. (Jack) Kane Chairman
- Justin Spencer Chairman, Board Member
- Jason Alger CFO, Chief Accounting Officer
- Patrick Nelli CFO
- Anne Marie Bickmore COO
- Benjamin Albert COO
- Dan LeSueur COO
- Dave Ross CTO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Health Catalyst, Inc. (HCAT) | The reported amounts represent the aggregate grant date fair value of awards of RSUs and PRSUs granted in each year presented, computed in accordance with FASB ASC Topic 718, excluding the estimate of forfeitures not related to the performance-based vesting of PRSUs. Amounts reflect the fair value of each award based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. The grant date fair value of the PRSUs is based on the probable outcome of the vesting conditions as of the grant date. For fiscal 2023, the grant date fair value of all long-term PRSUs at maximum performance achievement, are $0, $675,500, $205,760, $270,200, $168,875, and $236,425 for Messrs. Burton, Hunt, Landry, Orenstein, Alger, Horstmeier, and Ms. Llewelyn, respectively. Represents the cash amounts earned by our named executive officers under our short-term incentive plan (the Bonus Plan), based on our achievement of certain corporate performance goals. For a description of the Bonus Plan, see the section titled “Compensation Discussion and Analysis – Annual Performance-Based Incentives” above. For fiscal 2023, the amounts reported represent matching contributions made by us under our 401(k) plan ($0 for Mr. Burton, $12,945 for Mr. Hunt, $13,200 for Ms. Llewelyn, $10,736 for Mr. Landry, $5,882 for Mr. Orenstein, $12,758 for Mr. Alger, and $6,122 for Mr. Horstmeier), spot bonuses paid by us ($20,000 for Mr. Hunt and $8,000 for Mr. Alger) in recognition of extraordinary effort and performance during fiscal 2023, executive life insurance premiums paid by us ($926 for Ms. Llewelyn, $363 for Mr. Horstmeier, and $257 for Mr. Orenstein), executive long-term disability insurance premiums paid by us ($1,983 Ms. Llewelyn and $1,021 for Mr. Horstmeier), and gift cards paid by us as part of a benefit provided to all team members ($731 for Mr. Hunt, $22 for Ms. Llewelyn, $612 for Mr. Landry, and $568 for Mr. Alger). Mr. Burton voluntarily reduced his cash and new equity compensation by 100% from July 2022 through December 2023 in response to the challenging macroeconomic environment and to lead by example as part of our cost reduction initiatives. As part of his compensation reduction, he also declined receiving the cash portion of his annual bonus. Mr. Hunt and the company mutually agreed that he would step down as Chief Financial Officer effective March 1, 2024. After stepping down, Mr. Hunt continued to be employed by the company as a Senior Advisor until April 1, 2024, at which point he and the company entered into a separation and release agreement and an independent contractor agreement. | $300,000 | $1,519,532 |
| 2021 | Health Catalyst, Inc. (HCAT) | The reported amounts represent the aggregate grant date fair value of awards of RSUs and PRSUs granted in each year presented, computed in accordance with FASB ASC Topic 718, excluding the estimate of forfeitures not related to the performance-based vesting of PRSUs. Amounts reflect the fair value of each award based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. The grant date fair value of the PRSUs is based on the probable outcome of the vesting conditions as of the grant date. For fiscal 2023, the grant date fair value of all long-term PRSUs at maximum performance achievement, are $0, $675,500, $205,760, $270,200, $168,875, and $236,425 for Messrs. Burton, Hunt, Landry, Orenstein, Alger, Horstmeier, and Ms. Llewelyn, respectively. Represents the cash amounts earned by our named executive officers under our short-term incentive plan (the Bonus Plan), based on our achievement of certain corporate performance goals. For a description of the Bonus Plan, see the section titled “Compensation Discussion and Analysis – Annual Performance-Based Incentives” above. For fiscal 2023, the amounts reported represent matching contributions made by us under our 401(k) plan ($0 for Mr. Burton, $12,945 for Mr. Hunt, $13,200 for Ms. Llewelyn, $10,736 for Mr. Landry, $5,882 for Mr. Orenstein, $12,758 for Mr. Alger, and $6,122 for Mr. Horstmeier), spot bonuses paid by us ($20,000 for Mr. Hunt and $8,000 for Mr. Alger) in recognition of extraordinary effort and performance during fiscal 2023, executive life insurance premiums paid by us ($926 for Ms. Llewelyn, $363 for Mr. Horstmeier, and $257 for Mr. Orenstein), executive long-term disability insurance premiums paid by us ($1,983 Ms. Llewelyn and $1,021 for Mr. Horstmeier), and gift cards paid by us as part of a benefit provided to all team members ($731 for Mr. Hunt, $22 for Ms. Llewelyn, $612 for Mr. Landry, and $568 for Mr. Alger). Mr. Burton voluntarily reduced his cash and new equity compensation by 100% from July 2022 through December 2023 in response to the challenging macroeconomic environment and to lead by example as part of our cost reduction initiatives. As part of his compensation reduction, he also declined receiving the cash portion of his annual bonus. Mr. Hunt and the company mutually agreed that he would step down as Chief Financial Officer effective March 1, 2024. After stepping down, Mr. Hunt continued to be employed by the company as a Senior Advisor until April 1, 2024, at which point he and the company entered into a separation and release agreement and an independent contractor agreement. | $300,000 | $1,718,043 |
| 2020 | Health Catalyst, Inc. (HCAT) | There were no stock options granted during the years presented. The reported amounts represent the aggregate grant date fair value of awards of RSUs and PRSUs granted in each year presented, computed in accordance with FASB ASC Topic 718, excluding the estimate of forfeitures not related to the performance-based vesting of PRSUs. Amounts reflect the fair value of each award based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. The grant date fair value of the PRSUs is based on the probable outcome of the vesting conditions as of the grant date. For fiscal 2022, the grant date fair value of all PRSUs at maximum performance achievement, including the long-term PRSUs granted to Messrs. Burton and Nelli, are $974,843, $108,869, $958,067, $142,367, $198,813 and $83,745 for Messrs Burton, Hunt, Nelli, Horstmeier, Freeman, and Mr. Orenstein, respectively. Represents the cash amounts earned by our named executive officers under our short-term incentive plan (the Bonus Plan), based on our achievement of certain corporate performance goals. For a description of the Bonus Plan, see “Compensation Discussion and Analysis – Annual Performance-Based Incentives” above. For fiscal 2022, the amounts reported represent matching contributions made by us under our 401(k) plan ($8,607 for Mr. Burton, $10,500 for Mr. Hunt, $10,675 for Mr. Nelli, $10,675 for Mr. Horstmeier, $10,675 for Mr. Freeman, and $9,881 for Mr. Orenstein), equity modification value of $759,892 and cash severance of $258,740 related to Mr. Nelli’s separation from the company, executive life insurance premiums paid by us ($289 for Mr. Burton, $398 for Mr. Nelli, $1,450 for Mr. Horstmeier, and $771 for Mr. Orenstein), executive long-term disability insurance premiums paid by us ($1,769 for Mr. Nelli and $4,084 for Mr. Horstmeier), and gift cards paid by us as part of a benefit provided to all team members ($283 for Mr. Hunt and $2 for Mr. Horstmeier). Mr. Burton voluntarily reduced his cash and new equity compensation by 100% from July 2022 through December 2023 in response to the challenging macroeconomic environment and to lead by example as part of our cost reduction initiatives.. Prior to his voluntary reduction, Mr. Burton’s annual salary was $300,000. As part of his compensation reduction, he also declined receiving the cash portion of his annual bonus. Mr. Hunt was not a named executive officer prior to fiscal 2021 and Mr. Freeman was not a named executive officer prior to fiscal 2022. Mr. Nelli and the company mutually agreed that he would step down as President in September 2022. After stepping down, Mr. Nelli continued to be employed by the company as a Senior Advisor until December 31, 2022, at which point he and the company finalized his separation agreement. Mr. Horstmeier stepped down as Chief Operating Officer in March 2023. After stepping down, Mr. Horstmeier has and is expected to continue to serve the company as a Senior Advisor. Mr. Orenstein will be stepping down as General Counsel effective April 30, 2023. After stepping down, Mr. Orenstein is expected to continue to serve the company as a Senior Advisor. | $300,000 | $1,710,044 |
Recent activity
No call appearances or filed executive changes recorded yet.